Searched for
CDMO PLAYERS IN PHARMA
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Geopolitical tensions keep markets nervous despite strong earnings: Dipan MehtaGeopolitical tensions, particularly the Iran crisis, are overshadowing strong corporate earnings, according to Dipan Mehta. While India Inc...
- Cohance Lifesciences shares slip 7% after Jefferies cuts target price, downgrades on weak Q4Cohance Lifesciences shares dropped significantly after reporting an 84% year-on-year decline in March-quarter net profit. Jefferies downgr...
- Earnings season is strong, but Q1 pain is coming: Dipan MehtaMarket expert Dipan Mehta finds India's current earnings season strong. He notes that future quarters will test corporate India due to pote...
- Crude shock temporary; pharma and EMS are the real bets: Abhay AgarwalGeopolitical fears are driving crude oil prices higher, but Piper Serica's Abhay Agarwal believes this is a temporary, sentiment-driven spi...
- Cohance Lifesciences shares skyrocket 20% on hiring former Cipla CEO Umang VohraShares of Cohance Lifesciences surged 20% on Monday after the appointment of former Cipla CEO Umang Vohra as its new Executive Chairman and...
- Now is the time to start deploying money into markets, says Nitin Raheja; here's where to lookIndian markets present attractive long-term investment opportunities following recent corrections, according to Nitin Raheja of Julius Baer...
- Why smallcap funds are still a buy: A long-term strategy from Aditya KhemaniSmallcap valuations seem high but underlying fundamentals have improved. Aditya Khemani of Invesco Mutual Fund sees this as a structural sh...
- Trump tariffs hit patented drugs: Jefferies, Nomura explain impact on pharma stocksThe US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. S...
- Market to stay in sideways zone without earnings boost; CDMO’s the best way to play pharma: Dipan MehtaDipan Mehta of Elixir Equities suggests the pharma sector is facing headwinds from potential US tariffs, impacting margins amid strong comp...
- Which pharma companies will benefit from latest government policies? Sumit Gupta explainsThe Indian pharmaceutical sector is poised for growth, driven by government support for R&D and manufacturing. Policies promoting bulk drug...
- Pharma stocks catch a cold as US softens stance on Biosecure ActShares of Syngene International dropped 5.7%, Piramal Pharma fell 4.2%, Lauras Labs and Neuland Laboratories declined 3% and Divi's Laborat...
- Suven, Cohance aim to double combined business revenue to Rs 6,000 cr by FY29Suven Pharmaceuticals and Cohance Lifesciences plan to merge and aim to double their revenue to Rs 6,000 crore by FY29 through organic and ...
- Akums Pharma placed at a vantage point in pharma growthAkums Drugs &Pharma, a prominent contract development and manufacturing company in India, launched an ₹1,856-crore IPO with ₹680 crore in f...
- Foram Parekh on what to bet on in pharma packForam Parekh shares insights on CDMO companies' positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about L...
- Merger effect! Suven Pharma shares jump 15% in 2 daysAfter the merger becomes effective, all shareholders of Cohance will be issued shares of Suven at the ratio of 11 shares of Suven for every...
- Suven-Cohance Lifesciences merger announced to create 1st listed PE-led contract manufacturer in Indian pharmaSuven has been 50% owned by Advent since 2022 acquisition, with the remaining with public and institutional shareholders while Cohance is w...
- Suven Pharma, Cohance Lifesciences to merge to bolster CDMO businessPromoter of Suven Pharma, Advent International, had said last year that it would merge the two businesses post the buyout of its significan...
- First up: Jefferies puts buy rating on Gland, Laurus LabsJefferies has initiated coverage on Gland Pharma and Laurus Labs with buy ratings as it believes that Indian contract development and manuf...
- Jefferies sees up to 21% upside in these two pharma stocksIt has a target of Rs 4,566 on Gland Pharma, valuing the stock at 36.5 times FY24 EPS, in line with its historical one-year forward of 37 t...
Load More
